Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive outlook. Financial performance shows improvement, with debt repayment and DSO enhancements. Product development is strong, with AI deployment plans and a healthy biotech market. Market strategy is optimistic, with increased RFP flow and stable bookings. Financial health is stable, with cost optimization and debt reduction. Shareholder returns are not explicitly mentioned but implied to be stable. The Q&A confirms positive sentiment, with cautious optimism in biotech and AI's role. Overall, the company's strong financial metrics, optimistic guidance, and operational improvements support a positive stock price prediction.
Key Financial Performance
Q4 Revenue $660.5 million, 5.2% lower year-over-year. The decline was driven primarily by lower pass-through costs in both clinical pharmacology and clinical development businesses as well as continued FSP headwinds.
Full Year 2025 Revenue $2,723.4 million, increased 1% year-over-year. The increase was driven primarily by higher revenue in the clinical pharmacology business, partially offset by lower FSP revenue.
Gross Cost Savings $153 million for the year, exceeding the original target. Achieved through rightsizing initiatives and cost optimization.
Net Cost Savings $93 million for the year, exceeding the original target. The difference between gross and net savings was reinvested back into the workforce.
Adjusted EBITDA (Q4) $54 million, compared to $56 million in the prior year period. The decline was driven primarily by the reintroduction of variable compensation, partially offset by cost savings initiatives.
Adjusted EBITDA (Full Year 2025) $189.9 million, towards the higher end of the guidance range. The decline versus the prior year was due to lower FSP revenue, clinical pharmacology mix, reintroduction of variable compensation, and lower R&D tax credits, offset by cost savings initiatives.
Operating Cash Flow (Q4) $129.1 million, exceeding expectations. Driven by significant improvement in days sales outstanding (DSO) and favorable payment timing.
Free Cash Flow (Q4) $121.6 million, exceeding expectations. Driven by improved cash collections and DSO.
Operating Cash Flow (Full Year 2025) $113.5 million, compared to $262.8 million in the prior year. The prior year benefited from securitization proceeds, but on a comparable basis, there was a $148.6 million improvement year-over-year.
Free Cash Flow (Full Year 2025) $88.3 million, compared to $237.3 million in the prior year. The prior year benefited from securitization proceeds, but on a comparable basis, there was a $148.9 million improvement year-over-year.
Days Sales Outstanding (DSO) 16 days at year-end, improving by 17 days sequentially and 24 days year-over-year. Reflects enhancements in order-to-cash processes.
Debt Repayment $76 million of senior secured notes repaid in Q4, using cash on hand. Since the spin, approximately 35% of original debt has been paid down.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled risk radar update to Xcellerate: The AI-enabled risk radar update to Xcellerate was in production, and tools like the CRA Mobile App, digital assistant, and Start My Day platform were advanced to increase productivity.
Feasibility intelligence engine: A pilot of the new feasibility intelligence engine was completed, enabling better-informed feasibility decisions to improve operational outcomes.
Biotech sector focus: Fortrea sharpened its focus on biotech opportunities, assembling biotech-ready teams to address unique constraints and needs of the biotech sector.
Global clinical pharmacology partnership: Secured a long-term clinical pharmacology partnership award with a top 5 large pharma company.
Operational cost savings: Achieved $153 million in gross savings and $93 million in net savings for 2025, exceeding targets.
Streamlined project management: Reduced touchpoints for customers and created more direct interaction with therapeutic and scientific leads.
AI and technology integration: Invested in AI, machine learning, and workflow automation to drive speed, reduce costs, and improve quality in clinical research.
Leadership changes: Appointed Aggie Gallagher as General Counsel and Dr. Scott Dove to lead Clinical Pharmacology. Dr. Oren Cohen transitioned to focus fully as Chief Medical Officer.
Commercial framework (3 Rs): Implemented a commercial framework focusing on reach, relevance, and repeat to rebuild growth and strengthen execution.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Challenging and uneven operating environment: The company faced a challenging and uneven operating environment, which could impact its ability to meet financial and operational targets.
Uneven recovery in the first half of 2026: The recovery is expected to be uneven in the first half of 2026, reflecting earlier business wins and market conditions.
Macroeconomic caution: The macroeconomic environment remains cautious, which could affect client budgets and decision-making timelines.
FSP headwinds: Continued headwinds in the Functional Service Provider (FSP) segment are impacting revenue.
Lower pass-through costs: Decline in pass-through costs due to study mix is affecting revenue.
AI concerns in the CRO sector: Concerns about how AI will impact the Contract Research Organization (CRO) sector, though the company views AI as a productivity lever rather than a threat.
Regulatory requirements: Evolving regulatory requirements necessitate alignment and risk-based quality management, which could increase operational complexity.
Softer bookings in early 2025: Softer bookings in the first half of 2025 are expected to impact revenue in 2026.
FSP revenue decline: Lower revenue in the FSP business segment is a continuing challenge.
Pass-through cost reductions: Anticipated reductions in pass-through costs are expected to impact revenue in 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Market Recovery and Demand Trends: The macro environment shows signs of stabilization and early recovery. Funding activity rebounded in the second half of 2025, with the strongest activity in Q4. Large pharma budgets have stabilized, and biotech funding flow is expected to improve through 2026. However, recovery is expected to be uneven in the first half of 2026, with momentum building in the second half as outsourcing trends remain steady and access to capital improves.
Revenue Guidance for 2026: Targeting revenue in the range of $2.55 billion to $2.65 billion, reflecting a year-over-year decline due to softer bookings in the first half of 2025, continued FSP headwinds, and anticipated reductions in pass-through costs.
Adjusted EBITDA Guidance for 2026: Targeting adjusted EBITDA in the range of $190 million to $220 million, driven by continued efforts to rightsize the business and improve efficiency and agility.
Cost Savings Initiatives: Targeting incremental cost reductions of approximately $70 million to $80 million in gross savings and $40 million to $50 million in net savings for 2026, moving closer to normalized compensation levels by year-end.
Cash Flow Expectations: Targeting positive full-year 2026 operating cash flow, with anticipated negative cash flow in Q1 due to variable compensation payouts and partial reversal of timing-related DSO benefits. Positive cash flow generation is expected over the remainder of the year.
Margin Improvement: Margin improvement is a multiyear journey, supported by revenue growth and structural cost actions. The company is targeting a path back to adjusted EBITDA margins more in line with peers over time.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk through the outlook for the biotech market, particularly regarding bookings and customer conversations?
A:The CEO expressed cautious optimism about the biotech market, noting signs of improvement, stabilization, and early recovery. Engagement levels with clients have increased, decision-making timelines have normalized, and constructive dialogues with both big and small pharma are ongoing. There is an increase in RFP flow from biotech customers, but the CEO remains cautious until more momentum is observed.
Q:Can you expand on the key margin levers and the potential flow-through to the bottom line if revenue increases?
A:The CFO highlighted revenue growth as the key driver for margin improvement. Cost savings and optimization efforts are helping to expand the bottom line despite measured revenue growth. If revenue increases, the company expects strong flow-through to the bottom line, especially as they address trapped demand and optimize costs.
Q:Are there any notable trends in bookings mix or timing, and what is the status of accounts payable?
A:The CEO noted that the bookings mix is in line with expectations, with strength in clinical pharmacology and full-service business. The CFO explained that accounts payable levels have decreased due to process improvements and the unwinding of spin-related factors, and they are expected to stabilize at current levels.
Q:Can you provide more detail on RFP flow, bookings mix, win rates, and new client acquisition?
A:The CEO reported an increase in RFP flow from biotech customers and a healthy mix of Phase II and Phase III studies in bookings. Win rates have been consistent, and executive-led engagements have helped address customer concerns. The company has seen growth in new-to-Fortrea clients, particularly in biotech.
Q:What are the expectations for Q1 revenue and margin performance?
A:The CFO expects Q1 revenue to be similar to last year, with slight margin improvement due to cost-saving initiatives. However, there will be some headwinds from variable compensation and early-year employment taxes.
Q:How are customer mix and clinical pharmacology trends impacting revenue growth?
A:The CEO clarified that customer diversification is progressing, and clinical pharmacology demand remains strong. However, a one-time large study with significant pass-throughs in 2025 will not repeat in 2026, impacting revenue growth. The company is focused on increasing organic capacity in clinical pharmacology.
Q:What is the company's perspective on AI's impact on CRO services and customer behavior?
A:The CEO stated that AI adoption in clinical trials is early and constrained by regulations. AI is seen as a productivity tool rather than a replacement, with potential to accelerate pipeline development. There has been no material change in customer outsourcing behavior due to AI, though it is a frequent topic of discussion.
Q:What are the expectations for direct fee revenue versus pass-through revenue in 2026, and how will this impact margins?
A:The CFO expects clinical pharmacology to grow with stable pass-throughs, while full-service business will face reductions due to the completion of certain studies. The mix of revenue will impact margins, with clinical pharmacology contributing positively.
Q:What is the company's long-term margin goal and timeline?
A:The CEO stated that the goal is mid-teens margins, which is appropriate for a pure-play CRO. This is a multi-year journey, and more details will be provided after a full year of operations and potentially during an Investor Day later in the year.
Q:How have cancellations and gross bookings trended?
A:Cancellations have remained at historically low levels, and gross bookings have been stable and consistent.
Q:What is the company's view on AI's impact on clinical trial operations?
A:The CEO noted that AI is improving task automation in areas like pharmacovigilance, centralized monitoring, and data management. However, it has not replaced human involvement in site relationships or data monitoring.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for achieving mid-teens margins, stating it is a multi-year journey and promising more information later. Additionally, they did not provide precise figures for gross bookings growth or cancellations, only stating that trends were stable.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anshul
CRA
CRO
Chief Executive
Chief Medical
Dr
Executive Officer
Full Conference
Medical Officer
Officer Director
Phase II
Rs
access
activity
backdrop
client difference
client experience
client relationship
community
demand
deployment
design
engine
excellence pillar
excellence project
experience client
expertise
feasibility
focus client
investigator
journey
momentum
outcome
physician
pillar excellence
platform
recovery
relevance
repeat
replacement
role
way client
FTRE Transcript
Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary presents mixed signals: a 5% revenue increase and a 10% net income rise are positive, but a 2% decline in operating margin is concerning. The Q&A section lacks clarity, and the strategic initiatives were not discussed, leaving uncertainties. The market cap indicates a moderate reaction, thus a neutral prediction.
Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate a positive outlook. Financial performance shows improvement, with debt repayment and DSO enhancements. Product development is strong, with AI deployment plans and a healthy biotech market. Market strategy is optimistic, with increased RFP flow and stable bookings. Financial health is stable, with cost optimization and debt reduction. Shareholder returns are not explicitly mentioned but implied to be stable. The Q&A confirms positive sentiment, with cautious optimism in biotech and AI's role. Overall, the company's strong financial metrics, optimistic guidance, and operational improvements support a positive stock price prediction.
Fortrea Holdings Inc. (FTRE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-2
FTRE Slides
Fortrea Q4 2025 slides: revenue dips, transformation advances amid headwinds2026-02-26
Fortrea Q3 2025 slides: Strategic initiatives drive stock surge despite earnings miss2025-11-05
Fortrea Q2 2025 slides: Revenue growth accelerates as new CEO takes helm2025-08-06
Fortrea Q1 2025 slides: $489M impairment charge overshadows EBITDA growth2025-05-12
FTRE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
